You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

B-cell antigens

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, B-Cell Trial in Langfang (CD19 and CD22 targeted CAR-T cells)

Not yet recruiting
  • Lymphoma, B-Cell
  • CD19 and CD22 targeted CAR-T cells
  • Langfang, Hebei, China
    Hebei Yanda Ludaopei Hospital
Dec 6, 2022

Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia Trial in Beijing

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • chimeric antigen receptor T cell
  • Beijing, Beijing, China
    Beijing Boren Hospital
Aug 12, 2022

Large B-cell Lymphoma Trial in Philadelphia (mosunetuzumab, glofitamab, obinutuzumab)

Recruiting
  • Large B-cell Lymphoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jul 21, 2022

Including miRNA-based Tumor Signatures in Diffuse Large B Cell

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • no intervention (observational study)
  • Napoli, Italy
  • +2 more
Feb 17, 2023

Head Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma Trial in Scottsdale, Chapel Hill (TSC-204-A0201, TSC-204-C0702,

Not yet recruiting
  • Head and Neck Cancer
  • +20 more
  • TSC-204-A0201
  • +4 more
  • Scottsdale, Arizona
  • +1 more
Aug 3, 2023

Melanoma Trial in Philadelphia (Mature dendritic cell (DC) vaccine, Cyclophosphamide 300mg/m^2, Pembrolizumab)

Active, not recruiting
  • Melanoma
  • Mature dendritic cell (DC) vaccine
  • +2 more
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Feb 2, 2023

Recurrent Glioblastoma Trial in Los Angeles (Activated T cells)

Not yet recruiting
  • Recurrent Glioblastoma
  • Activated T cells
  • Los Angeles, California
    Cedars-Sinai Medical Center
Apr 21, 2022

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell Trial in United Kingdom (ALETA-001)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • +4 more
  • Birmingham, United Kingdom
  • +5 more
Sep 18, 2023

Relapsed/Refractory Large B-Cell Lymphoma Trial in Beijing, Hangzhou (Prizloncabtagene autoleucel)

Recruiting
  • Relapsed/Refractory Large B-Cell Lymphoma
  • Prizloncabtagene autoleucel
  • Beijing, China
  • +1 more
Mar 24, 2023

B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)

Recruiting
  • B-Cell Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia
  • Tampa, Florida
    Moffitt Cancer Center
Nov 28, 2023

Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • RC19D2 cell injection
  • Tianjin, Tianjin, China
    Hematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023

Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

Not yet recruiting
  • Non Hodgkin's Lymphoma
  • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
  • +2 more
  • Beijing, China
  • +2 more
Aug 23, 2023

High-Dose Methotrexate Clearance in Diffuse Large B-Cell

Recruiting
  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional Study
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 8, 2023

B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • QH103 Cell Injection
  • +2 more
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Sep 21, 2023

Will Permit Sites to Proactively Assess TAA, HLA and HPV-16

Terminated
  • Head and Neck Cancer
  • +7 more
  • Tumor Profiling
  • Scottsdale, Arizona
  • +2 more
Dec 2, 2022

B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia Trial in Milwaukee (Dose Level -1: 0.75x10^6 cells/kg

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • B-cell Chronic Lymphocytic Leukemia
  • Dose Level -1: 0.75x10^6 cells/kg CAR20.19.22 cells
  • +3 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin and Froedtert Hospital
Jul 1, 2022

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

Not yet recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • +5 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2023

Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Not yet recruiting
  • Lymphoma, B-Cell
  • +6 more
  • Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
  • Guayaquil, Guayas, Ecuador
    Instituto Oncológico Nacional Dr. Juan Tanca Marengo
Apr 27, 2023

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

Hematopoietic Stem Cell Transplantation, Hematologic Malignancy Trial (CliniMACS®)

Not yet recruiting
  • Hematopoietic Stem Cell Transplantation
  • Hematologic Malignancy
  • CliniMACS®
  • (no location specified)
Oct 17, 2023

Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non-hodgkin Lymphoma,B Cell
  • Autologous CD19-STAR-T cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2022

Large B-cell Lymphoma Trial (Glofitamab, Polatuzumab vedotin, Obinutuzumab)

Not yet recruiting
  • Large B-cell Lymphoma
  • (no location specified)
Oct 3, 2023